Jennison Associates LLC Lowers Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Jennison Associates LLC reduced its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 28.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 293,588 shares of the company’s stock after selling 117,349 shares during the period. Jennison Associates LLC owned 0.59% of Prestige Consumer Healthcare worth $22,926,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. DAVENPORT & Co LLC acquired a new position in Prestige Consumer Healthcare during the fourth quarter worth approximately $1,212,000. Caprock Group LLC purchased a new stake in shares of Prestige Consumer Healthcare during the 4th quarter valued at $210,000. Pacer Advisors Inc. increased its holdings in shares of Prestige Consumer Healthcare by 83.0% during the 4th quarter. Pacer Advisors Inc. now owns 3,352 shares of the company’s stock worth $262,000 after buying an additional 1,520 shares during the last quarter. KBC Group NV raised its position in shares of Prestige Consumer Healthcare by 28.3% in the 4th quarter. KBC Group NV now owns 2,048 shares of the company’s stock worth $160,000 after buying an additional 452 shares during the period. Finally, Blue Trust Inc. boosted its holdings in Prestige Consumer Healthcare by 24.8% in the fourth quarter. Blue Trust Inc. now owns 2,190 shares of the company’s stock valued at $158,000 after acquiring an additional 435 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on PBH shares. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. DA Davidson reissued a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Finally, Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and an average price target of $85.25.

Prestige Consumer Healthcare Stock Up 0.1 %

NYSE PBH opened at $75.90 on Thursday. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a fifty-two week low of $60.00 and a fifty-two week high of $86.36. The business has a 50 day moving average price of $79.29 and a two-hundred day moving average price of $75.25. The stock has a market cap of $3.75 billion, a PE ratio of 18.47, a P/E/G ratio of 2.15 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same period last year, the business earned $1.07 EPS. The business’s revenue was down .9% on a year-over-year basis. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.46 EPS for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 9,885 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the transaction, the senior vice president now owns 18,835 shares in the company, valued at approximately $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider William P’pool sold 8,987 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 in the last ninety days. Insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.